Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bellerophon Ther Com (BLPH)

Bellerophon Ther Com (BLPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 428
  • Shares Outstanding, K 12,233
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,830 K
  • 60-Month Beta 0.70
  • Price/Sales 0.19
  • Price/Cash Flow N/A
  • Price/Book 0.12
Trade BLPH with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.33
  • Most Recent Earnings $-0.16 on 11/14/23
  • Next Earnings Date 09/23/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0350 unch
on 09/18/24
0.0350 unch
on 09/18/24
unch (unch)
since 08/16/24
3-Month
0.0350 unch
on 09/18/24
0.0666 -47.45%
on 06/20/24
-0.0264 (-43.00%)
since 06/18/24
52-Week
0.0290 +20.69%
on 11/17/23
0.4526 -92.27%
on 09/20/23
-0.3750 (-91.46%)
since 09/18/23

Most Recent Stories

More News
Bellerophon Therapeutics: Q3 Earnings Snapshot

Bellerophon Therapeutics: Q3 Earnings Snapshot

BLPH : 0.0350 (unch)
Bellerophon Therapeutics: Q1 Earnings Snapshot

Bellerophon Therapeutics: Q1 Earnings Snapshot

BLPH : 0.0350 (unch)
Bellerophon Therapeutics: Q3 Earnings Snapshot

Bellerophon Therapeutics: Q3 Earnings Snapshot

BLPH : 0.0350 (unch)
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference

WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0350 (unch)
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results

WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0350 (unch)
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results

WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0350 (unch)
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference

WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0350 (unch)
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis

Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial Treatment...

BLPH : 0.0350 (unch)
Bellerophon Therapeutics: Q3 Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Monday reported a loss of $4.6 million in its third quarter.

BLPH : 0.0350 (unch)
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results

WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage...

BLPH : 0.0350 (unch)

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

3rd Resistance Point 0.0350
2nd Resistance Point 0.0350
1st Resistance Point 0.0350
Last Price 0.0350
1st Support Level 0.0350
2nd Support Level 0.0350
3rd Support Level 0.0350

See More

52-Week High 0.4526
Fibonacci 61.8% 0.2908
Fibonacci 50% 0.2408
Fibonacci 38.2% 0.1908
Last Price 0.0350
52-Week Low 0.0290

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar